If you are among those companies looking to go public in the near future, now is the time to get your house in order. Photo via Getty Images

Home to a wealth of world-changing innovations and a highly skilled labor pool, Houston has attracted startups and digital tech firms for years. Today, the city stands at the forefront of a promising era with seven Houston startups beginning the year strong with more than $380 million in venture funding, and the city ranked among the top emerging startup ecosystems in North America

Houston-based startups planning their exit strategies have good reason to be optimistic about an initial public offering, or IPO, market that is expected to grow in 2024. After a two-year slump in startup investing, some market watchers are predicting that the IPO window may reopen as the economy improves and inflation and interest rates cool.

But good timing requires good readiness. The window of opportunity for preparation now appears to be a microwindow. As any company that went public at the peak of the dot-com or post-COVID booms can attest, preparation is essential to quickly take action when the time is right. Hitting that microwindow will require that IPO-bound Houston companies be strategic about their IPO readiness planning. A lack of planning can result in an IPO experience that is not well planned, and potentially a missed opportunity altogether.

It’s unclear when the next IPO window will open, or for how long the window will remain open, but it could happen quicker than expected. This unpredictability suggests that Houston startups seeking to go public should start their legal, financial, and regulatory planning now. The important period for many companies planning an IPO begins six to 18 months prior to listing and lasts until the six months post-IPO.

Readying an IPO

We gained several insights from our discussions with CEOs and CFOs who have effectively navigated IPOs recently to provide insights for companies contemplating going public when the next microwindow opens. A company’s comprehensive readiness plan can be key to performing well in the market, whether it is up or down. Summarized below are common key areas that challenged many C-Suite executives in being a public company and, in hindsight, areas they wished they had addressed earlier in the process.

  1. Internal forecasting. Internal forecasting is paramount. In fact, it’s one of the primary takeaways cited in our conversations with the C-suite execs who went through the IPO process. Houston companies on an IPO track should be prepared to provide accurate forecasting and timely fulfillment of projections. Missing projections can result in significant regulatory repercussions.
  1. Key performance indicators and non-GAAP measures. Take reasonable steps towards performing a comprehensive benchmarking study to determine relevant KPIs and non-GAAP measures and metrics to report upon; be ready with the frameworks in place to report upon during quarterly and annual reporting.
  1. Growth story. The ability to communicate the company’s growth story can be essential to an effective IPO. Company leaders should be able to clearly convey topics such as the company’s growth, vision and strategy, its plans for improving performance metrics, the market opportunity, its competitive edge, and how its product or services will meet market demand. Meetings with analysts and other market influencers are also necessary to gain investor support. The executives we talked to said that when they did not invest time in this awareness-building step, they often found themselves rushing to get the word out as the offering date closed in.
  1. Finance infrastructure and human capital. Understand the infrastructure and operating model required to operate as a public company, along with the human capital necessary to sustain operations. Identifying the necessary skillsets and bandwidth within the team supports a smoother IPO process. Collaborating with experienced, independent advisors is also vital. These advisors assist in organizing the process, outlining SEC reporting requirements, updating SEC-compliant financial reporting, preparing Management Discussion and Analysis (MD&A) and pro forma financial information, and offering guidance throughout the pre-IPO preparation.
  1. Governance. IPO-bound companies need to anticipate new corporate governance requirements as a publicly traded entity, particularly in terms of their board of directors. Proper governance and board oversight can be essential to support the quality of financial statements produced by management. Executives told us that recruiting the right board members is often a significant pre-IPO challenge. Identifying these members early is crucial, as the right resources may not be available later.

Closing thoughts

If you are among those companies looking to go public in the near future, now is the time to get your house in order. Companies are often surprised to discover how much preparation it truly takes to operate as a public company. In fact, we typically recommend starting the preparation journey 18 to 24 months before the anticipated public listing date. Simply stated, if you wait until the IPO window opens before gearing up, you likely will be gearing up for the next window.

Deloitte’s complimentary IPO SelfAssess tool can help you gauge your ability to go public with a tailored assessment. The tool provides you with useful insights and identifies potential areas for improvement based on the feedback you provide.

------

Will Braeutigam is the U.S. capital markets transactions leader at Deloitte & Touche LLP. Laura Evans is audit and assurance partner at Deloitte & Touche LLP.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Eli Lilly breaks ground on $6.5B pharmaceutical factory in Houston

lilly lands

Leading pharmaceutical company Eli Lilly broke ground today, Sept. 21, on its $6.5 billion manufacturing site at Houston's Generation Park.

The 236-acre, state-of-the art factory is expected to come online in 2030 and will manufacture Foundayo, the company's first synthetic oral GLP-1 medication, as well as other advanced therapeutics.

"We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas," David Ricks, Lilly chair and CEO, said in a prepared statement. "This $6.5 billion investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”

Houston was up against more than 300 locations in the U.S. for the factory, as part of Lilly’s $50 billion investment in domestic medicine production that has launched 10 manufacturing sites since 2020. Lilly first announced Houston had been selected for the site last September.

Photo via gov.texas.gov

As Abbott mentioned, the site is expected to create hundreds of jobs, and will hire engineers, scientists, operations personnel and lab technicians once up and running. It will create 4,000 construction jobs while being built.

In an effort to support workforce development, Lilly also announced a $12.5 million commitment to Houston's San Jacinto College in addition to a $2.5 million charitable donation to the San Jacinto College Foundation. The funding will go toward hands-on training, equipment and facilities to support future technicians, operators, maintenance professionals, and other manufacturing talent, according to Lilly. The charitable donation will fund scholarships for students.

"This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region,” Brenda Hellyer, chancellor of San Jacinto College, said in the release.

"When you invest in a place like Houston, you invest in its people first," Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added. "This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We're hiring across the greater Houston area to help residents build careers close to home."

Rendering courtesy Eli Lilly

Lilly previously said it chose Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, because of factors such as financial incentives, access to utilities and transportation and the region’s business-friendly environment. Generation Park is home to campuses for San Jacinto College and Lone Star College.

Since Lilly first announced plans for the site, another fellow pharma giant has made plans to move into Generation Park. Bristol Myers Squibb Co. announced last month that it would build a $2.3 billion factory in the district. The site is expected to manufacture small molecule, biologic and antibody-drug conjugates and will also come online around 2030. Read more here.

UH Health names leader of new digital health institute

new exec

Recently launched UH Health has named the first-ever executive director of its new Institute for Digital Healthcare Transformation at the University of Houston.

Beto López has been tapped to lead the new initiative that aims to help develop and commercialize health care technologies centered around university research.

Launched in August, the Institute for Digital Healthcare Transformation leans on experts from UH’s engineering, medicine, business, law and other departments and will connect with industry partners. It will initially focus on mobile health applications, sensors, wearables and artificial intelligence, according to UH.

“Most digital health initiatives and commercialization efforts start with the technology and hope adoption follows. But the translation gap isn't a science problem — it’s a scaffolding problem between researchers, the community and the market,” López said in a news release. “I've spent the past 10 years building that scaffolding in places that weren’t wired for it, and I'm looking forward to building it here at UH to help ensure new health care technologies reach the people and communities that can benefit from them most.”

López previously spent 10 years at San Francisco-based innovation consultancy company IDEO, where he led over 100 projects for Fortune 500 companies and public agencies. He co-founded and served as managing director of the Design Institute for Health at UT Austin’s Dell Medical School; and also co-founded a social venture studio/venture capital fund focused on health care innovation. He worked alongside Houston’s Legacy Community Health during the COVID-19 pandemic.

“Beto understands that breakthrough technology alone doesn't transform health care — it has to be designed around the needs of patients, providers and communities and have a clear path into practice,” Jonathan McCullers, vice president for health affairs at UH, added in the news release. “His experience spanning academic health care and venture capital equips him to bring together researchers, health care organizations, entrepreneurs and investors. This makes him uniquely suited to lead this institute and help turn the university's innovation into solutions that improve people's lives.”

The University of Houston launched UH Health, its new cross-disciplinary academic venture, in July. It aims to bring together the university's health-related education, research and community impact under one umbrella.

ExxonMobil gets approval for $5B Texas Gulf Coast carbon capture project

CCS Expansion

Spring-based ExxonMobil has won approval from the Texas Railroad Commission for a $5 billion carbon capture and storage project in East Texas.

Dominic Genetti, senior vice president of CCS at ExxonMobil, told The Financial Times, which broke the news, that the Railroad Commission’s action is a “major milestone” that lets the company keep expanding along the Gulf Coast. In a 2-1 vote, commissioners authorized a carbon sequestration permit for the project.

“The Railroad Commission clearly recognizes the important role carbon capture and storage can play in meeting growing global demand for lower-carbon products while supporting new jobs and economic growth,” Genetti said.

The U.S. Environmental Protection Agency (EPA) approved ExxonMobil’s Rose CCS project last year.

The project will enable the company to inject about 53 metric tons of industrial customers’ carbon emissions into three underground wells it drilled in the Beaumont-Port Arthur area. Over a 13-year period, ExxonMobil plans to inject about 4 million metric tons per year into the Fleming and Upper Frio rock formations, according to Carbon Herald.

ExxonMobil says it owns the world’s first and largest CCS system, comprising 1,300 miles of CO2 pipeline and secure storage sites. Seventy percent of the pipelines are along the Gulf Coast.

The company ramped up its CCS business in 2023 with the $4.9 billion purchase of Denbury, which owned about 1,000 miles of CO2 pipelines.

“Our expertise, combined with Denbury’s talent and CO2 pipeline network, expands our low-carbon leadership and best positions us to meet the decarbonization needs of industrial customers while also reducing emissions in our own operations,” ExxonMobil Chairman and CEO Darren Woods said when the deal closed.

In January, Genetti wrote in a post on ExxonMobil’s website that the company is committed to CCS “for the long haul.”

“CCS is not new technology, but it’s flown relatively under the radar compared with the attention that production of hydrocarbons commands,” he wrote. “Now, as the world becomes more aware of the need to reduce emissions, CCS finally has a brighter spotlight and a broader runway to scale up.”

The company also announced this week that it has begun CCS operations at a direct reduced iron facility in Convent, Louisiana. The project will capture, transport and store up to 800,000 metric tons of CO2 per year, according to the company.

---

This article first appeared on EnergyCapitalHTX.com.